Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment

Jitender Bariwal, Virender Kumar, Hao Chen, Rajan Sharma Bhattarai, Yang Peng, Wei Li, Ram I. Mahato

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Melanoma is the most aggressive type of skin cancer, which readily metastasizes through lymph nodes to the lungs, liver, and brain. Since the repeated administration of most chemotherapeutic drugs develops chemoresistance and severe systemic toxicities, herein we synthesized 2-(4-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (abbreviated as QW-296), a novel tubulin destabilizing agent with little susceptible to transporter-mediated drug resistance. QW-296 disturbed the microtubule dynamics at the nanomolar concentration in A375 and B16F10 melanoma cells. QW-296 binding to colchicine-binding site on tubulin protein was confirmed by molecular modeling and tubulin polymerization assay. QW-296 significantly inhibited A375 and B16F10 cell proliferation, induced G2/M cell cycle arrest and led to apoptosis and cell death. To improve its aqueous solubility, QW-296 was encapsulated into methoxy poly(ethyleneglycol)-b-poly(carbonate-co-lactide) [mPEG-b-P(CB-co-LA)] polymeric nanoparticles by solvent evaporation, with the mean particle size of 122.0 ± 2.28 nm and drug loading of 3.70% (w/w). Systemic administration of QW-296 loaded nanoparticles into C57/BL6 albino mice bearing lung metastatic melanoma at the dose of 20 mg/kg 4 times a week for 1.5 weeks resulted in significant tumor regression and prolonged mouse median survival without significant change in mouse body weight. In conclusion, QW-296 loaded nanoparticles have the potential to treat metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)231-243
Number of pages13
JournalJournal of Controlled Release
Volume309
DOIs
StatePublished - Sep 10 2019

Fingerprint

Microtubules
Melanoma
Tubulin
Nanoparticles
G2 Phase Cell Cycle Checkpoints
Lung
Carbonates
Colchicine
Skin Neoplasms
Particle Size
Drug Resistance
Polymerization
Pharmaceutical Preparations
Solubility
Cell Death
Lymph Nodes
Binding Sites
Body Weight
Cell Proliferation
Apoptosis

Keywords

  • Melanoma
  • Microtubule/tubulin inhibitor
  • Nanoparticles
  • Tubulin polymerization

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment. / Bariwal, Jitender; Kumar, Virender; Chen, Hao; Bhattarai, Rajan Sharma; Peng, Yang; Li, Wei; Mahato, Ram I.

In: Journal of Controlled Release, Vol. 309, 10.09.2019, p. 231-243.

Research output: Contribution to journalArticle

Bariwal, Jitender ; Kumar, Virender ; Chen, Hao ; Bhattarai, Rajan Sharma ; Peng, Yang ; Li, Wei ; Mahato, Ram I. / Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment. In: Journal of Controlled Release. 2019 ; Vol. 309. pp. 231-243.
@article{17481547208745d3a2bc93c9d2844856,
title = "Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment",
abstract = "Melanoma is the most aggressive type of skin cancer, which readily metastasizes through lymph nodes to the lungs, liver, and brain. Since the repeated administration of most chemotherapeutic drugs develops chemoresistance and severe systemic toxicities, herein we synthesized 2-(4-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (abbreviated as QW-296), a novel tubulin destabilizing agent with little susceptible to transporter-mediated drug resistance. QW-296 disturbed the microtubule dynamics at the nanomolar concentration in A375 and B16F10 melanoma cells. QW-296 binding to colchicine-binding site on tubulin protein was confirmed by molecular modeling and tubulin polymerization assay. QW-296 significantly inhibited A375 and B16F10 cell proliferation, induced G2/M cell cycle arrest and led to apoptosis and cell death. To improve its aqueous solubility, QW-296 was encapsulated into methoxy poly(ethyleneglycol)-b-poly(carbonate-co-lactide) [mPEG-b-P(CB-co-LA)] polymeric nanoparticles by solvent evaporation, with the mean particle size of 122.0 ± 2.28 nm and drug loading of 3.70{\%} (w/w). Systemic administration of QW-296 loaded nanoparticles into C57/BL6 albino mice bearing lung metastatic melanoma at the dose of 20 mg/kg 4 times a week for 1.5 weeks resulted in significant tumor regression and prolonged mouse median survival without significant change in mouse body weight. In conclusion, QW-296 loaded nanoparticles have the potential to treat metastatic melanoma.",
keywords = "Melanoma, Microtubule/tubulin inhibitor, Nanoparticles, Tubulin polymerization",
author = "Jitender Bariwal and Virender Kumar and Hao Chen and Bhattarai, {Rajan Sharma} and Yang Peng and Wei Li and Mahato, {Ram I.}",
year = "2019",
month = "9",
day = "10",
doi = "10.1016/j.jconrel.2019.07.025",
language = "English (US)",
volume = "309",
pages = "231--243",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment

AU - Bariwal, Jitender

AU - Kumar, Virender

AU - Chen, Hao

AU - Bhattarai, Rajan Sharma

AU - Peng, Yang

AU - Li, Wei

AU - Mahato, Ram I.

PY - 2019/9/10

Y1 - 2019/9/10

N2 - Melanoma is the most aggressive type of skin cancer, which readily metastasizes through lymph nodes to the lungs, liver, and brain. Since the repeated administration of most chemotherapeutic drugs develops chemoresistance and severe systemic toxicities, herein we synthesized 2-(4-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (abbreviated as QW-296), a novel tubulin destabilizing agent with little susceptible to transporter-mediated drug resistance. QW-296 disturbed the microtubule dynamics at the nanomolar concentration in A375 and B16F10 melanoma cells. QW-296 binding to colchicine-binding site on tubulin protein was confirmed by molecular modeling and tubulin polymerization assay. QW-296 significantly inhibited A375 and B16F10 cell proliferation, induced G2/M cell cycle arrest and led to apoptosis and cell death. To improve its aqueous solubility, QW-296 was encapsulated into methoxy poly(ethyleneglycol)-b-poly(carbonate-co-lactide) [mPEG-b-P(CB-co-LA)] polymeric nanoparticles by solvent evaporation, with the mean particle size of 122.0 ± 2.28 nm and drug loading of 3.70% (w/w). Systemic administration of QW-296 loaded nanoparticles into C57/BL6 albino mice bearing lung metastatic melanoma at the dose of 20 mg/kg 4 times a week for 1.5 weeks resulted in significant tumor regression and prolonged mouse median survival without significant change in mouse body weight. In conclusion, QW-296 loaded nanoparticles have the potential to treat metastatic melanoma.

AB - Melanoma is the most aggressive type of skin cancer, which readily metastasizes through lymph nodes to the lungs, liver, and brain. Since the repeated administration of most chemotherapeutic drugs develops chemoresistance and severe systemic toxicities, herein we synthesized 2-(4-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (abbreviated as QW-296), a novel tubulin destabilizing agent with little susceptible to transporter-mediated drug resistance. QW-296 disturbed the microtubule dynamics at the nanomolar concentration in A375 and B16F10 melanoma cells. QW-296 binding to colchicine-binding site on tubulin protein was confirmed by molecular modeling and tubulin polymerization assay. QW-296 significantly inhibited A375 and B16F10 cell proliferation, induced G2/M cell cycle arrest and led to apoptosis and cell death. To improve its aqueous solubility, QW-296 was encapsulated into methoxy poly(ethyleneglycol)-b-poly(carbonate-co-lactide) [mPEG-b-P(CB-co-LA)] polymeric nanoparticles by solvent evaporation, with the mean particle size of 122.0 ± 2.28 nm and drug loading of 3.70% (w/w). Systemic administration of QW-296 loaded nanoparticles into C57/BL6 albino mice bearing lung metastatic melanoma at the dose of 20 mg/kg 4 times a week for 1.5 weeks resulted in significant tumor regression and prolonged mouse median survival without significant change in mouse body weight. In conclusion, QW-296 loaded nanoparticles have the potential to treat metastatic melanoma.

KW - Melanoma

KW - Microtubule/tubulin inhibitor

KW - Nanoparticles

KW - Tubulin polymerization

UR - http://www.scopus.com/inward/record.url?scp=85070102021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070102021&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2019.07.025

DO - 10.1016/j.jconrel.2019.07.025

M3 - Article

C2 - 31330213

AN - SCOPUS:85070102021

VL - 309

SP - 231

EP - 243

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -